Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | PHASE3 | COMPLETED | 49 | — | — | Aug 1, 2013 | May 5, 2017 | Jun 26, 2020 | 9 | United States |
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Infusion of one MPC expanded cord unit and one unexpanded cord unit. |
| Control | ACTIVE_COMPARATOR | Infusion of two unexpanded cord blood units. |
| Name | Type | Description |
|---|---|---|
| Infusion of one MPC expanded cord unit and one unexpanded cord unit | BIOLOGICAL | Infusion of one MPC expanded cord unit and one unexpanded cord unit. |
| Infusion of two unexpanded cord blood units. | BIOLOGICAL | Umbilical Cord Blood. |
Inclusion Criteria: * Patient must have one of the following: * Acute myelogenous leukemia (AML) in complete morphological remission at study screening (Complete Remission with Incomplete Platelet Recovery (CRp) acceptable). * Acute lymphoblastic leukemia (ALL) in complete morphological remiss...